MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma

2019 ◽  
Vol 29 (3) ◽  
pp. 357-363 ◽  
Author(s):  
Jana Ivanidze ◽  
Mark Lum ◽  
David Pisapia ◽  
Rajiv Magge ◽  
Rohan Ramakrishna ◽  
...  
Keyword(s):  
Tert Promoter Mutation ◽  
Promoter Mutation ◽  
Mutation Status ◽  
Tert Promoter ◽  
Mri Features

Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting

2017 ◽  
Vol 471 (5) ◽  
pp. 641-649 ◽  
Author(s):  
Ekkehard Hewer ◽  
Nadine Prebil ◽  
Sabina Berezowska ◽  
Marielena Gutt-Will ◽  
Philippe Schucht ◽  
...  
Keyword(s):  
Clinical Setting ◽  
Tert Promoter Mutation ◽  
Promoter Mutation ◽  
Mutation Status ◽  
Tert Promoter ◽  
Routine Clinical Setting ◽  
Diffuse Gliomas

scholarly journals TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma

2014 ◽  
Vol 106 (9) ◽  
Author(s):  
Klaus G. Griewank ◽  
Rajmohan Murali ◽  
Joan Anton Puig-Butille ◽  
Bastian Schilling ◽  
Elisabeth Livingstone ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cutaneous Melanoma ◽  
Independent Prognostic Factor ◽  
Tert Promoter Mutation ◽  
Promoter Mutation ◽  
Mutation Status ◽  
Tert Promoter

Effect of ARMS-qPCR on detection sensitivity of earlier diagnosis of papillary thyroid cancers with worse prognosis determined by BRAF V600E and TERT promoter mutation coexisting.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 6588-6588
Author(s):  
Peng-cheng Yu ◽  
Li-cheng Tan ◽  
Xiao Shi ◽  
Ben Ma ◽  
Wen-jun Wei ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Recurrence Rate ◽  
Braf V600e ◽  
Tert Promoter Mutation ◽  
Papillary Thyroid ◽  
Promoter Mutation ◽  
Mutation Status ◽  
Tert Promoter ◽  
Worse Prognosis ◽  
Sensitive Method

6588 Background: Co-existing of BRAF V600E and TERT promoter C228T/C250T mutation has been extensively related to prognosis in thyroid cancer. Our study aimed to establish a more sensitive method for mutation detection and explore the correlation more in-depth. Methods: BRAF and TERT promoter mutation status of 250 papillary thyroid cancer was detected by both Amplification Refractory Mutation System quantitative PCR (ARMS-qPCR) and Sanger sequencing to compare the sensitivity. The associations between the mutation status and the clinicopathological features were analyzed. Results: ARMS-qPCR displayed higher sensitivity than Sanger ( BRAF V600E: 75.2% vs. 52.4%, p< 0.001; TERT promoter C228T/C250T: 12.0% vs. 3.6%, p= 0.001; Co-mutation (9.6% vs. 3.2%, p= 0.005). Both methods indicated that patients with BRAF V600E and TERT promoter co-mutation were higher in age at diagnosis (ARMS-qPCR: 51.0 ± 14.2 vs. 40.2 ± 12.6, p <0.001; Sanger: 64.3 ± 7.1 vs. 40.5 ± 12.6, p <0.001), and the recurrence rate (16.7% vs. 3.1%, p= 0.014; 50.0% vs. 2.9%, p< 0.001), besides, the co-mutation group were related to more advanced TNM stage ( p< 0.001; p< 0.001) and higher MACIS score (5.1 ± 1.5 vs. 4.2 ± 0.7, p= 0.006; 6.6 ± 1.1 vs. 4.2 ± 0.8, p< 0.001). In addition, compared with the co-mutation results of Sanger, it seems that ARMS-qPCR has identified an earlier stage of group, which were younger (43.3 ± 10.1 vs. 66.4 ± 6.1, p< 0.001), and with smaller tumor (1.8 ± 1.5 vs. 4.0 ± 1.3, p= 0.002), as well as lower recurrence rate ( 0.0% vs. 50%, p= 0.007). Besides, the newly identified group were lower in MACIS score (4.2 ± 0.8 vs. 6.9 ± 0.7, p= 0.002) and with lower TNM stage ( p= 0.001). Conclusions: Patients with BRAF V600E and TERT promoter C228T/C250T co-mutation have a worse prognosis. Using ARMS-qPCR, the more sensitive method could identify earlier stages of patients with a potentially worse prognosis. [Table: see text]

scholarly journals Comparative study of TERT promoter mutation status within spatially, temporally and morphologically distinct components of urothelial carcinoma

2017 ◽  
Vol 72 (2) ◽  
pp. 354-356 ◽  
Author(s):  
Noah A Brown ◽  
Madelyn Lew ◽  
Helmut C Weigelin ◽  
Alon Z Weizer ◽  
Jeffrey S Montgomery ◽  
...  
Keyword(s):  
Comparative Study ◽  
Urothelial Carcinoma ◽  
Tert Promoter Mutation ◽  
Promoter Mutation ◽  
Mutation Status ◽  
Tert Promoter
Sign in / Sign up

Export Citation Format

Share Document